5.3 EBV/PTLD, HHV-6 Encephalitis, BK Cystitis, Adenovirus, HSV & VZV
Key Takeaways
- EBV monitoring and preemptive rituximab apply to risk-defined patients and platforms; tissue diagnosis, disease distribution, immunosuppression reduction and cellular/oncologic therapy are individualized for PTLD.
- Evaluate HHV-6 encephalitis, BK hemorrhagic cystitis, adenovirus, HSV and VZV from syndrome and risk. PCR positivity alone is not always disease, and treatment/supportive care is pathogen- and organ-specific.
- HHV-6 limbic encephalitis characteristically presents with sudden short-term memory impairment, confusion, and seizures in the early post-transplant window, and it is a recognized cause of post-engraftment cytopenias and graft failure.
- BK polyomavirus-associated hemorrhagic cystitis is managed with hydration and urine flow that avoids overload, analgesia, urologic management of clots or obstruction, and correction of thrombocytopenia or coagulopathy; cidofovir and other antivirals are off-label with uncertain benefit and meaningful renal toxicity.
1. Epstein-Barr Virus and PTLD
EBV risk rises with T-cell depletion, ATG/alemtuzumab, mismatched or cord grafts, severe GVHD therapy and delayed immune recovery. Use quantitative EBV monitoring for risk-defined recipients at the interval specified by platform. A rising viral load prompts reassessment; no universal assay threshold mandates the same dose of rituximab in every patient.
PTLD may present with fever, lymphadenopathy, extranodal lesions, cytopenias or organ dysfunction. Imaging and tissue diagnosis are pursued when feasible because histology and distribution guide care. Management may include reduction of immunosuppression when safe, rituximab for CD20-positive disease, chemotherapy, surgery/radiation for selected disease, EBV-specific T cells, or clinical trials. Monitor infection, hepatitis B reactivation risk, immunoglobulins and cytopenias.
2. Other Critical Viral Pathogens: HHV-6, BK Polyomavirus, Adenovirus, HSV & VZV
Human Herpesvirus-6 (HHV-6) Limbic Encephalitis
- Biology: HHV-6B reactivates in 40–50% of allogeneic recipients between Day +14 and Day +30, with peak incidence in umbilical cord blood and haploidentical transplants.
- Hallmark Clinical Triad:
- Acute anterograde amnesia (profound loss of short-term recall; patient cannot remember recent conversations or names of relatives).
- Severe insomnia, agitation, and delirium.
- Complex partial or generalized seizures.
- Diagnostics: High-titer HHV-6 PCR in Cerebrospinal Fluid (CSF); brain MRI reveals bilateral hyperintensity in the medial temporal lobes and limbic system on T2/FLAIR sequences.
- Treatment: Urgent infectious-disease/neurologic assessment and treatment with foscarnet or ganciclovir selected and adjusted for renal function, marrow reserve and current guidance; duration follows clinical and CSF response.
BK Polyomavirus-Associated Hemorrhagic Cystitis
Dysuria, frequency, bladder pain, clots and hematuria after HCT prompt urinalysis/culture, BK testing and evaluation for adenovirus, bacterial infection, medication/conditioning injury, stones and coagulopathy. Support hydration and urine flow without causing overload; provide analgesia orally or intravenously, manage clots/obstruction with urology, and correct thrombocytopenia/coagulopathy. Cidofovir and other antiviral approaches are off-label with uncertain benefit and meaningful renal toxicity. Avoid rectal medications when neutropenia, thrombocytopenia or mucosal injury makes them unsafe.
Adenovirus Infections
- Spectrum: Causes severe necrotizing hepatitis, hemorrhagic colitis, pneumonitis, and hemorrhagic cystitis, particularly in pediatric cord blood recipients.
- Monitoring & Treatment: Use syndrome- and risk-directed quantitative PCR and tissue evaluation when needed. Reduction of immunosuppression and cidofovir/brincidofovir or virus-specific cellular approaches are specialist decisions with important toxicity and access limitations.
Herpes Simplex Virus (HSV) & Varicella-Zoster Virus (VZV) Prophylaxis
- Prevention: HSV/VZV-active prophylaxis is common for seropositive HCT recipients, but agent, renal-adjusted dose, route and duration follow graft, immune suppression, absorption and the program protocol.
- Duration: Initiated on Day 0 and continued for a minimum of 1 year post-transplant, or indefinitely until systemic immunosuppression for chronic GVHD is entirely discontinued.
3. Community Respiratory Viruses and the Progression Question
Respiratory syncytial virus, influenza, parainfluenza, human metapneumovirus, rhinovirus, and SARS-CoV-2 behave very differently after transplant than in immunocompetent hosts. The clinically decisive question is not which virus was detected but whether infection has progressed from the upper to the lower respiratory tract, because lower-tract disease carries substantially higher mortality and changes therapy, monitoring, and isolation.
Upper-tract disease presents as rhinorrhea, sore throat, sinus congestion, and cough with clear lungs and no hypoxia. Lower-tract disease adds dyspnea, a new oxygen requirement, and infiltrates on imaging. Progression is most likely in patients who are lymphopenic, still pre-engraftment, receiving high-dose corticosteroids, or within the first hundred days.
Nursing priorities are concrete:
- Test early and specifically. Send the multiplex respiratory panel from the ordered source. A negative nasopharyngeal swab does not exclude lower-tract disease in a hypoxic patient, and bronchoalveolar lavage may be required.
- Isolate on suspicion, not on confirmation. Precautions differ by organism and by institution, so apply that pathogen's precaution set rather than one generic respiratory bundle.
- Treat a new oxygen requirement as an escalation event. A rising oxygen need is the earliest reliable marker of progression and outranks the fever curve.
- Reduce transmission at the source. Screen visitors, defer symptomatic caregivers, and reinforce hand hygiene, because most post-transplant respiratory viruses are introduced by close contacts.
Antiviral options are pathogen-specific and narrow. Influenza has label-supported neuraminidase-inhibitor therapy that works best when started early, while RSV, parainfluenza, and metapneumovirus have no uniformly effective licensed antiviral in this population; management centers on supportive care, immunosuppression review, and specialist decisions about investigational or off-label agents. Never extrapolate one virus's treatment to another.
4. Comparative Surveillance Reference
| Pathogen | Typical window | First-line diagnostic | Nursing red flag |
|---|---|---|---|
| EBV and PTLD | Weeks to months; earlier with T-cell depletion | Quantitative plasma PCR, with tissue diagnosis for PTLD | Rising load with new adenopathy, fever, or organ dysfunction |
| HHV-6 | Approximately Day +14 to +30 | CSF PCR with MRI when encephalitis is suspected | New short-term memory loss, agitation, or seizure |
| BK polyomavirus | Weeks after conditioning, often post-engraftment | Urinalysis and BK testing after excluding other causes | Clot retention, obstruction, or falling hemoglobin |
| Adenovirus | Early; higher in cord blood and pediatric recipients | Syndrome-directed quantitative PCR, tissue when needed | Rising load with hepatitis, colitis, or pneumonitis |
| HSV and VZV | Any time without effective prophylaxis | Lesion PCR alongside the clinical dermatomal pattern | Any new vesicular rash, especially crossing dermatomes |
| Respiratory viruses | Seasonal, any phase | Multiplex respiratory panel; BAL if lower tract suspected | New or rising oxygen requirement |
The unifying principle across this table is that a positive nucleic acid test is a data point, not a diagnosis. Each pathogen requires the nurse to pair the assay result with a syndrome, a risk profile, and a timeline before it means anything. Reporting "the BK PCR is positive" changes nothing; reporting "the BK PCR is positive and the patient now has clot retention and a two-gram hemoglobin drop" changes the plan the same hour.
On Day +21 post-allogeneic umbilical cord blood transplant, a 34-year-old male develops sudden, profound short-term memory impairment. He is unable to recall what he ate for breakfast or recognize that his transplant occurred three weeks ago, but his long-term memory remains intact. Over the next 12 hours, he develops severe insomnia, agitation, and a new onset focal motor seizure. A brain MRI demonstrates bilateral hyperintensity in the medial temporal lobes. What is the most likely diagnosis and first-line treatment?
A 28-year-old male on Day +45 post-allogeneic peripheral blood stem cell transplant is receiving high-dose prednisone for Grade III acute GI GVHD. Surveillance blood work reveals an exponential rise in plasma quantitative EBV PCR to 150,000 copies/mL. On physical exam, he has new painless cervical lymphadenopathy and low-grade fevers. What is the initial targeted medical therapy of choice?